Phase I clinical trial of HC-1119: A deuterated form of enzalutamide

Xiaoyu Li, Ke Cheng, Xinghai Li, Yuwen Zhou, Jiyan Liu, Hao Zeng, Yuanwei Chen, Xiao Liu, Ying Zhang, Yongsheng Wang, Feng Bi, Li Zheng, Xiaoyu Li, Ke Cheng, Xinghai Li, Yuwen Zhou, Jiyan Liu, Hao Zeng, Yuanwei Chen, Xiao Liu, Ying Zhang, Yongsheng Wang, Feng Bi, Li Zheng

Abstract

The purpose of our study was to investigate the safety, pharmacokinetics (PK), and initial antitumor efficacy of HC-1119 in patients with metastatic castration-resistant prostate cancer (mCRPC). Eligible mCRPC patients were included in our study (NCT03774056) with two parts. Part A was a dose escalation study in which patients received a dose escalation of HC-1119 (40, 80, 160 and 200 mg/day). Part B was a dose expansion study in which patients received HC-1119 at the dose of 80 and 160 mg. Safety assessment and pharmacokinetic samplings were performed for all patients at the given time points; preliminary tumor response was also assessed. Twenty-four patients were enrolled in part A and 19 patients in part B, respectively. HC-1119 was safe, well tolerated and no dose-limiting toxicity was observed. Fatigue was the most common treatment-related adverse event and no seizures were observed. At the dose levels of 40, 80 and 160 mg, the AUC and Cmax of HC-1119 in plasma increased almost dose-proportionally at the steady state in mCRPC patients. Maximum prostate-specific antigen (PSA) response rates (≥50% reduction from the baseline) in dose escalation and dose expansion cohorts were 77% and 75%, respectively; the overall disease control rate (22 patients available for imaging analysis) was 72.7%, with PR in 4 patients, SD in 12 patients and PD in 6 patients; the 2-year overall survival rate in patients from Part B was 56.8%. HC-1119 was safe, well tolerated and efficacious and HC-1119 at 80 mg/day is recommended for further studies.

Keywords: HC-1119; androgen receptor (AR) antagonist; castration-resistant prostate cancer (CRPC); deuteration; phase I.

© 2021 UICC.

References

REFERENCES

    1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019;69(1):7-34.
    1. Palmberg C, Koivisto P, Visakorpi T, Tammela TL. PSA decline is an independent prognostic marker in hormonally treated prostate cancer. Eur Urol. 1999;36(3):191-196.
    1. Gittes RF. Carcinoma of the prostate. N Engl J Med. 1991;324(4):236-245.
    1. Crawford ED, Eisenberger MA, McLeod DG, et al. A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Engl J Med. 1989;321(7):419-424.
    1. Denis LJ, Carnelro de Moura JL, Bono A, et al. Goserelin acetate and flutamide versus bilateral orchiectomy: a phase III EORTC trial (30853). EORTC GU Group and EORTC Data Center. Urology. 1993;42(2):119-129. discussion 129-130.
    1. Scher HI, Fizazi K, Saad F, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med. 2012;367(13):1187-1197.
    1. Wen L, Yao J, Valderrama A. Evaluation of treatment patterns and costs in patients with prostate cancer and bone metastases. J Manag Care Spec Pharm. 2019;25(3-b suppl):S1-S11.
    1. Schalken J, Fitzpatrick JM. Enzalutamide: targeting the androgen signalling pathway in metastatic castration-resistant prostate cancer. BJU Int. 2016;117(2):215-225.
    1. Tran C, Ouk S, Clegg NJ, et al. Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science. 2009;324(5928):787-790.
    1. Nelson SD, Trager WF. The use of deuterium isotope effects to probe the active site properties, mechanism of cytochrome P450-catalyzed reactions, and mechanisms of metabolically dependent toxicity. Drug Metab Dispos. 2003;31(12):1481-1498.
    1. Sharma R, Strelevitz TJ, Gao H, et al. Deuterium isotope effects on drug pharmacokinetics. I system-dependent effects of specific deuteration with aldehyde oxidase cleared drugs. Drug Metab Dispos. 2012;40(3):625-634.
    1. Zhong L, Hou C, Zhang L, Zhao J, Li F, Li W. Synthesis of deuterium-enriched sorafenib derivatives and evaluation of their biological activities. Mol Divers. 2019;23(2):341-350.
    1. Pang X, Peng L, Chen Y. Effect of N-methyl deuteration on pharmacokinetics and pharmacodynamics of enzalutamide. J Label Comp Radiopharm. 2017;60(9):401-409.
    1. Jiang J, Pang X, Li L, et al. Effect of N-methyl deuteration on metabolism and pharmacokinetics of enzalutamide. Drug Des Dev Ther. 2016;10:2181-2191.
    1. Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials. 1989;10(1):1-10.
    1. Sanderson K. Big interest in heavy drugs. Nature. 2009;458(7236):269. .
    1. Katsnelson A. Heavy drugs draw heavy interest from pharma backers. Nat Med. 2013;19(6):656.
    1. Gant TG. Using deuterium in drug discovery: leaving the label in the drug. J Med Chem. 2014;57(9):3595-3611.
    1. Frank S. Tetrabenazine: the first approved drug for the treatment of chorea in US patients with Huntington disease. Neuropsychiatr Dis Treat. 2010;6:657-665. .
    1. Joulia ML, Carton E, Jouinot A, et al. Pharmacokinetic/pharmacodynamic relationship of enzalutamide and its active metabolite N-desmethyl enzalutamide in metastatic castration-resistant prostate cancer patients. Clin Genitourin Cancer. 2020;18(2):155-160.
    1. Higano CS, Beer TM, Taplin ME, et al. Long-term safety and antitumor activity in the phase 1-2 study of enzalutamide in pre- and post-docetaxel castration-resistant prostate cancer. Eur Urol. 2015;68(5):795-801.
    1. Golshayan AR, Antonarakis ES. Enzalutamide: an evidence-based review of its use in the treatment of prostate cancer. Core Evid. 2013;8:27-35.

Source: PubMed

Sponsorer og samarbejdspartnere

Medicinske tilstande

Narkotikainterventioner

3
Abonner